Oral anticoagulation monotherapy significantly reduces bleeding and improves net clinical benefit in stable CAD patients without increasing ischemic risk.
Does oral anticoagulation monotherapy reduce bleeding and improve net clinical benefit compared to oral anticoagulation combined with antiplatelet therapy in patients with stable coronary artery disease requiring anticoagulation?
In patients with stable CAD requiring anticoagulation, OAC monotherapy (particularly with DOACs) is the preferred long-term strategy as it reduces bleeding without increasing ischemic risk.
Absolute Event Rate: 0% vs 0%
In patients with stable CAD requiring OAC, OAC monotherapy significantly reduces bleeding and improves net clinical benefit without increasing ischemic risk. These findings support OAC monotherapy, particularly with DOACs, as the preferred long-term strategy, especially in East Asian populations.
Ibrahim et al. (Thu,) reported a other. Oral anticoagulation monotherapy significantly reduces bleeding and improves net clinical benefit in stable CAD patients without increasing ischemic risk.